Intellia Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Intellia Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 156,172,000 | 126,880,000 | 189,182,000 | 120,495,000 | 130,849,000 | 171,979,000 | 226,748,000 | 168,027,000 | 171,806,000 | 294,150,000 | 523,506,000 | 141,194,000 | 147,781,000 | 133,382,000 | 123,406,000 | 334,736,000 | 129,879,000 | 141,538,000 | 160,020,000 | 179,746,000 | 361,687,000 | 80,993,000 | 57,226,000 | 38,440,000 | 49,140,000 | 47,097,000 | 58,856,000 | 293,248,000 | 305,538,000 | 327,778,000 | 340,678,000 | 222,264,000 | 241,047,000 | 257,551,000 | 273,064,000 | 290,618,000 | 300,687,000 | 64,192,000 |
| marketable securities | 303,479,000 | 376,867,000 | 412,333,000 | 537,619,000 | 560,219,000 | 619,315,000 | 685,475,000 | 686,761,000 | 736,268,000 | 639,392,000 | 669,116,000 | 687,000,000 | 726,494,000 | 721,869,000 | 625,282,000 | 463,531,000 | 399,140,000 | 442,525,000 | 437,351,000 | 228,201,000 | 75,117,000 | 169,266,000 | 222,500,000 | 249,485,000 | 255,203,000 | |||||||||||||
| accounts receivable | 11,353,000 | 10,504,000 | 8,517,000 | 8,854,000 | 12,329,000 | 36,427,000 | 36,456,000 | 6,491,000 | 5,056,000 | 4,906,000 | 3,768,000 | 4,023,000 | 2,854,000 | 1,801,000 | 2,031,000 | 2,491,000 | 1,993,000 | 953,000 | 2,130,000 | 1,217,000 | 3,864,000 | 13,368,000 | 4,620,000 | 3,599,000 | 4,188,000 | 3,591,000 | 7,547,000 | 2,813,000 | 8,609,000 | 7,466,000 | 10,471,000 | 4,493,000 | 2,764,000 | 2,443,000 | 6,454,000 | 1,112,000 | 1,000,000 | 1,000,000 |
| prepaid expenses and other current assets | 24,941,000 | 37,141,000 | 29,831,000 | 43,934,000 | 53,814,000 | 56,322,000 | 49,651,000 | 32,214,000 | 26,485,000 | 25,223,000 | 20,407,000 | 26,730,000 | 18,304,000 | 18,315,000 | 18,584,000 | 14,016,000 | 18,392,000 | 16,068,000 | 17,016,000 | 7,086,000 | 5,699,000 | 6,133,000 | 5,135,000 | 6,414,000 | 4,710,000 | 3,520,000 | 3,371,000 | 2,768,000 | 3,482,000 | 2,476,000 | 3,681,000 | 2,296,000 | 2,108,000 | 1,084,000 | 1,788,000 | 972,000 | 1,217,000 | 745,000 |
| total current assets | 495,945,000 | 551,392,000 | 639,863,000 | 710,902,000 | 757,211,000 | 884,043,000 | 998,330,000 | 893,493,000 | 939,615,000 | 963,671,000 | 1,216,797,000 | 858,947,000 | 895,433,000 | 875,367,000 | 769,303,000 | 814,774,000 | 549,404,000 | 601,084,000 | 616,517,000 | 416,250,000 | 446,367,000 | 269,760,000 | 289,481,000 | 295,935,000 | 307,137,000 | 303,693,000 | 324,977,000 | 298,829,000 | 317,629,000 | 337,720,000 | 354,830,000 | 229,053,000 | 245,919,000 | 261,078,000 | 281,306,000 | 292,702,000 | 302,904,000 | 65,937,000 |
| marketable securities - noncurrent | 170,855,000 | 203,353,000 | 260,215,000 | 286,567,000 | 248,805,000 | 162,090,000 | 99,864,000 | 137,752,000 | 164,013,000 | 225,038,000 | 69,338,000 | 20,533,000 | 32,604,000 | 139,486,000 | 337,361,000 | 350,451,000 | 22,262,000 | 16,735,000 | 4,746,000 | 9,868,000 | 4,739,000 | |||||||||||||||||
| property and equipment | 22,806,000 | 25,123,000 | 27,381,000 | 28,763,000 | 30,273,000 | 32,075,000 | 32,760,000 | 33,800,000 | 33,194,000 | 31,606,000 | 27,921,000 | 26,597,000 | 25,868,000 | 23,697,000 | 20,968,000 | 19,946,000 | 18,530,000 | 16,157,000 | 15,943,000 | 15,612,000 | 16,402,000 | 17,251,000 | 17,996,000 | 17,206,000 | 16,694,000 | 16,669,000 | 17,061,000 | 16,935,000 | 16,580,000 | 16,010,000 | 15,272,000 | 13,560,000 | 12,578,000 | 11,418,000 | 10,628,000 | 5,492,000 | 4,421,000 | 4,228,000 |
| operating lease right-of-use assets | 129,045,000 | 137,979,000 | 219,292,000 | 100,331,000 | 105,412,000 | 110,424,000 | 115,375,000 | 118,775,000 | 123,550,000 | 128,265,000 | 133,076,000 | 101,290,000 | 73,775,000 | 76,473,000 | 79,143,000 | 81,788,000 | 77,070,000 | 77,912,000 | 39,114,000 | 22,210,000 | 23,469,000 | 24,918,000 | 19,137,000 | 20,663,000 | 20,923,000 | 21,012,000 | ||||||||||||
| investments and other assets | 80,243,000 | 68,316,000 | 44,264,000 | 46,788,000 | 49,835,000 | 70,957,000 | 42,883,000 | 42,363,000 | 41,031,000 | 40,920,000 | 40,527,000 | 36,989,000 | 37,128,000 | 35,493,000 | 29,558,000 | |||||||||||||||||||||||
| total assets | 898,894,000 | 986,163,000 | 1,191,015,000 | 1,173,351,000 | 1,191,536,000 | 1,259,589,000 | 1,300,977,000 | 1,243,349,000 | 1,323,240,000 | 1,417,889,000 | 1,520,114,000 | 1,084,458,000 | 1,110,424,000 | 1,202,788,000 | 1,294,464,000 | 1,334,961,000 | 672,243,000 | 716,891,000 | 676,322,000 | 458,555,000 | 490,830,000 | 314,752,000 | 334,280,000 | 346,635,000 | 352,441,000 | 344,363,000 | 347,315,000 | 321,233,000 | 339,778,000 | 359,545,000 | 376,235,000 | 249,170,000 | 264,975,000 | 279,263,000 | 298,969,000 | 301,469,000 | 310,624,000 | 75,540,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||
| accounts payable | 9,802,000 | 12,364,000 | 14,589,000 | 13,145,000 | 18,816,000 | 13,689,000 | 7,452,000 | 3,553,000 | 11,634,000 | 6,890,000 | 5,154,000 | 4,384,000 | 7,515,000 | 10,138,000 | 9,653,000 | 7,470,000 | 6,854,000 | 8,688,000 | 10,460,000 | 7,775,000 | 7,000 | 3,870,000 | 3,941,000 | 4,548,000 | 1,848,000 | 3,687,000 | 2,708,000 | 1,754,000 | 335,000 | 1,916,000 | 2,172,000 | 2,194,000 | 2,267,000 | 1,434,000 | 4,652,000 | 657,000 | 1,042,000 | 1,206,000 |
| accrued expenses | 41,553,000 | 40,805,000 | 55,355,000 | 51,206,000 | 45,127,000 | 43,276,000 | 67,017,000 | 57,979,000 | 49,534,000 | 44,822,000 | 60,876,000 | 58,379,000 | 44,871,000 | 42,876,000 | 43,309,000 | 24,633,000 | 37,150,000 | 21,215,000 | 25,554,000 | 19,348,000 | 15,374,000 | 13,102,000 | 13,273,000 | 11,644,000 | 11,898,000 | 7,735,000 | 10,742,000 | 9,893,000 | 9,156,000 | 6,605,000 | 7,999,000 | 5,939,000 | 5,312,000 | 3,559,000 | 5,900,000 | 4,810,000 | 4,288,000 | 2,973,000 |
| current portion of operating lease liability | 26,990,000 | 38,763,000 | 20,246,000 | 19,177,000 | 18,963,000 | 18,763,000 | 18,599,000 | 17,074,000 | 16,750,000 | 16,328,000 | 16,685,000 | 13,551,000 | 9,568,000 | 9,338,000 | 9,112,000 | 8,705,000 | 7,415,000 | 8,255,000 | 5,696,000 | 6,198,000 | 5,834,000 | 5,693,000 | 5,745,000 | |||||||||||||||
| current portion of deferred revenue | 17,154,000 | 20,661,000 | 20,661,000 | 22,155,000 | 22,184,000 | 22,184,000 | 22,140,000 | 13,347,000 | 21,933,000 | 35,343,000 | 43,839,000 | 54,818,000 | 61,806,000 | 63,759,000 | 63,759,000 | 56,759,000 | 22,544,000 | 22,544,000 | 22,544,000 | 22,544,000 | 37,927,000 | 12,639,000 | 12,674,000 | 15,822,000 | 19,652,000 | 23,431,000 | 27,122,000 | 14,268,000 | 15,678,000 | 17,062,000 | 21,188,000 | 17,653,000 | 18,792,000 | 19,917,000 | 20,178,000 | 17,166,000 | 16,287,000 | 6,781,000 |
| total current liabilities | 95,499,000 | 112,593,000 | 110,851,000 | 105,683,000 | 105,090,000 | 97,912,000 | 115,208,000 | 91,953,000 | 99,851,000 | 103,383,000 | 126,554,000 | 131,132,000 | 123,760,000 | 126,111,000 | 125,833,000 | 97,567,000 | 73,963,000 | 60,702,000 | 64,254,000 | 55,865,000 | 59,142,000 | 35,304,000 | 35,633,000 | 37,519,000 | 38,463,000 | 39,234,000 | 40,572,000 | 25,915,000 | 25,169,000 | 25,583,000 | 31,359,000 | 25,786,000 | 26,371,000 | 24,910,000 | 30,730,000 | 22,633,000 | 21,617,000 | 10,960,000 |
| deferred revenue, net of current portion | 12,539,000 | 13,161,000 | 18,256,000 | 22,607,000 | 28,052,000 | 33,440,000 | 38,853,000 | 12,719,000 | 12,919,000 | 13,862,000 | 19,932,000 | 25,678,000 | 35,330,000 | 49,481,000 | 63,476,000 | 63,023,000 | 40,208,000 | 45,829,000 | 51,387,000 | 57,070,000 | 62,752,000 | 13,020,000 | 16,136,000 | 19,322,000 | 22,508,000 | 25,659,000 | 28,810,000 | 31,996,000 | 35,181,000 | 38,332,000 | 44,111,000 | 47,336,000 | 50,785,000 | 54,092,000 | 58,109,000 | 60,406,000 | 65,042,000 | 2,753,000 |
| long-term operating lease liability | 75,601,000 | 80,490,000 | 189,952,000 | 82,446,000 | 87,332,000 | 92,100,000 | 96,747,000 | 101,263,000 | 105,582,000 | 109,801,000 | 114,018,000 | 84,097,000 | 59,997,000 | 62,480,000 | 64,911,000 | 67,273,000 | 63,259,000 | 64,487,000 | 33,609,000 | 16,000,000 | 17,349,000 | 18,669,000 | 12,630,000 | |||||||||||||||
| total liabilities | 183,639,000 | 206,244,000 | 319,059,000 | 210,736,000 | 220,474,000 | 223,452,000 | 250,808,000 | 205,935,000 | ||||||||||||||||||||||||||||||
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||
| common stock | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 8,000 | 8,000 | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | |
| additional paid-in capital | 3,107,576,000 | 3,070,581,000 | 3,048,741,000 | 3,007,810,000 | 2,884,997,000 | 2,802,889,000 | 2,710,797,000 | 2,567,195,000 | 2,512,741,000 | 2,473,825,000 | 2,420,223,000 | 1,898,091,000 | 1,840,644,000 | 1,811,681,000 | 1,745,870,000 | 1,729,029,000 | 1,044,939,000 | 1,027,192,000 | 962,173,000 | 722,500,000 | 716,503,000 | 580,065,000 | 570,493,000 | 547,913,000 | 525,574,000 | 487,559,000 | 478,968,000 | 445,225,000 | 438,589,000 | 432,533,000 | 421,706,000 | 272,993,000 | 269,375,000 | 266,080,000 | 263,403,000 | 261,127,000 | 259,123,000 | 1,483,000 |
| accumulated other comprehensive income | 653,000 | 1,057,000 | 605,000 | 3,297,000 | -13,000 | -12,000 | 1,000 | 31,000 | 155,000 | 373,000 | 261,000 | 336,000 | 255,000 | 59,000 | ||||||||||||||||||||||||
| accumulated deficit | -2,392,984,000 | -2,291,729,000 | -2,177,400,000 | -2,048,502,000 | -1,912,790,000 | -1,765,815,000 | -1,658,379,000 | -1,526,218,000 | -1,403,994,000 | -1,280,313,000 | -1,177,187,000 | -1,063,780,000 | -950,551,000 | -849,873,000 | -703,001,000 | -621,764,000 | -550,120,000 | -481,314,000 | -435,109,000 | -392,917,000 | -365,077,000 | -332,684,000 | -300,878,000 | -272,602,000 | -248,968,000 | -223,285,000 | -201,025,000 | -181,959,000 | -159,257,000 | -137,038,000 | -121,113,000 | -97,150,000 | -81,794,000 | -66,201,000 | -53,570,000 | -43,007,000 | -35,525,000 | -28,625,000 |
| total stockholders’ equity | 715,255,000 | 779,919,000 | 871,956,000 | 962,615,000 | 971,062,000 | 1,036,137,000 | 1,050,169,000 | 1,037,414,000 | 1,104,888,000 | 1,190,843,000 | 1,235,584,000 | 824,951,000 | 880,547,000 | 953,754,000 | 1,040,244,000 | 1,107,098,000 | 494,813,000 | 545,873,000 | 527,072,000 | 329,620,000 | 351,587,000 | 247,759,000 | 269,881,000 | 275,652,000 | 276,866,000 | 264,338,000 | 277,920,000 | 300,597,000 | 199,883,000 | 209,837,000 | 218,124,000 | 223,602,000 | ||||||
| total liabilities and stockholders’ equity | 898,894,000 | 986,163,000 | 1,191,015,000 | 1,173,351,000 | 1,191,536,000 | 1,259,589,000 | 1,300,977,000 | 1,243,349,000 | 1,323,240,000 | 1,417,889,000 | 1,520,114,000 | 1,084,458,000 | 1,110,424,000 | 1,202,788,000 | 1,294,464,000 | 1,334,961,000 | 672,243,000 | 716,891,000 | 676,322,000 | 458,555,000 | 490,830,000 | 314,752,000 | 334,280,000 | 346,635,000 | 352,441,000 | 344,363,000 | 347,315,000 | 376,235,000 | 279,263,000 | 298,969,000 | 301,469,000 | 310,624,000 | ||||||
| equity method investment | 11,765,000 | 17,166,000 | 21,837,000 | 28,389,000 | 32,455,000 | 40,102,000 | 45,616,000 | 52,272,000 | 58,131,000 | 62,837,000 | ||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -1,155,000 | -947,000 | -2,258,000 | -3,572,000 | -3,868,000 | -2,678,000 | -7,461,000 | -9,368,000 | -9,554,000 | -8,062,000 | -28,000 | |||||||||||||||||||||||||||
| contingent consideration liability | 24,026,000 | 18,600,000 | ||||||||||||||||||||||||||||||||||||
| other long-term liabilities | 10,790,000 | 10,962,000 | 13,000 | 52,000 | 92,000 | 131,000 | 168,000 | 201,000 | 234,000 | 378,000 | 293,000 | 306,000 | 363,000 | 349,000 | ||||||||||||||||||||||||
| accumulated other comprehensive (loss)/income | -2,632,000 | -174,000 | ||||||||||||||||||||||||||||||||||||
| other assets | 5,165,000 | 4,977,000 | 5,003,000 | 4,748,000 | 4,483,000 | 4,592,000 | 2,823,000 | 2,920,000 | 2,963,000 | 2,948,000 | 2,989,000 | 5,277,000 | 5,469,000 | 5,569,000 | 5,815,000 | 6,133,000 | 6,557,000 | 6,478,000 | 6,767,000 | 7,035,000 | 3,275,000 | 3,299,000 | 5,375,000 | |||||||||||||||
| marketable securities - current | 247,482,000 | 221,959,000 | ||||||||||||||||||||||||||||||||||||
| current portion of lease liability | 5,505,000 | 5,065,000 | 4,381,000 | |||||||||||||||||||||||||||||||||||
| long-term lease liability | 14,142,000 | 14,604,000 | 15,132,000 | |||||||||||||||||||||||||||||||||||
| proceeds due from at-the-market offerings | 27,140,000 | |||||||||||||||||||||||||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||||||||||||||||||||
| total stockholders' equity | 263,270,000 | 279,336,000 | 295,499,000 | 175,847,000 | 187,585,000 | |||||||||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 321,233,000 | 339,778,000 | 359,545,000 | 249,170,000 | 264,975,000 | |||||||||||||||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||
| convertible preferred stock (series b, series a-2, series a-1, junior and founder), 0.0001 par value; 5,000,000 shares and 36,500,000 shares authorized, respectively; 0 shares and 36,316,628 shares issued and outstanding, respectively | ||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||
| convertible preferred stock (series b, series a-2, series a-1, junior and founder), 0.0001 par value; 36,500,000 shares authorized and 36,316,628 shares issued and outstanding; aggregate liquidation preference of 95,946 | 88,620,000 | |||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -27,142,000 | |||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ deficit | 75,540,000 | |||||||||||||||||||||||||||||||||||||
| collaboration revenue | 1,777,000 | |||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||
| research and development | 5,225,000 | |||||||||||||||||||||||||||||||||||||
| general and administrative | 3,246,000 | |||||||||||||||||||||||||||||||||||||
| total operating expenses | 8,471,000 | |||||||||||||||||||||||||||||||||||||
| operating income | -6,694,000 | |||||||||||||||||||||||||||||||||||||
| interest income | 5,000 | |||||||||||||||||||||||||||||||||||||
| income before income taxes | -6,689,000 | |||||||||||||||||||||||||||||||||||||
| benefit from income taxes | ||||||||||||||||||||||||||||||||||||||
| net income | -6,689,000 | |||||||||||||||||||||||||||||||||||||
| net income per common unit, basic and diluted | ||||||||||||||||||||||||||||||||||||||
| net income per share | -9,890 | |||||||||||||||||||||||||||||||||||||
| weighted-average common units outstanding, basic and diluted | ||||||||||||||||||||||||||||||||||||||
| weighted-average shares outstanding, basic and diluted | 676,000 |
We provide you with 20 years of balance sheets for Intellia Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Intellia Therapeutics. Explore the full financial landscape of Intellia Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Intellia Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.